Related Experiment Video
Updated: Sep 26, 2026

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
Published on: October 3, 2012
Apoptosis and Parkinson's disease
Nirit Lev1, Eldad Melamed, Daniel Offen
1Neurosciences Laboratory, Department of Neurology, Felsenstein Medical Research Center, Sackler School of Medicine, Rabin Medical Center, Beilinson Campus, 49100, Petach Tikva, Israel.
Abstract:
Parkinson's disease (PD) is a severe and progressive neurodegenerative disease. It is the second most common neurodegenerative disease, after Alzheimer's disease. It is caused by the selective loss of the dopaminergic neurons in the substantia nigra (SN) pars compacta. Although subject to intensive research, the etiology of PD is still enigmatic and treatment is basically symptomatic. Many factors are thought to operate in the mechanism of cell death of the nigrostriatal dopaminergic neurons in PD. In recent years, evidence for the role of apoptotic cell death in PD arises from morphological, as well as molecular, studies in cell cultures, animal models for PD, as well as human studies on postmortem brains from PD patients. These studies indicate that apoptosis takes place in PD and that there is a proapoptotic environment in the nigrostriatal region of parkinsonian patients. It is of utmost importance to conclusively determine the mode of cell death in PD because new "antiapoptotic" compounds may offer a means of protecting neurons from cell death and of slowing the rate of neurodegeneration and disease progression.
Related Concept Videos
Parkinson Disease ll: Pathophysiology
Parkinson Disease l: Introduction
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Apoptosis
Neural Regulation